ANDA 209549, held by Watson Labs Teva. Teriflunomide.
As of Nov 16, 2026, ANDA 209549 (Teriflunomide), held by Watson Labs Teva, was first approved by FDA on Jul 27, 2018, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 27, 2018 | Original application | Approved |
| Teriflunomide7MG · tablet;oral | Teriflunomide | Discontinued |
| Teriflunomide14MG · tablet;oral | Teriflunomide | Discontinued |
| Dec 1, 2022 | Supplement 1Labeling · Standard review | Approved | None posted |
| Dec 1, 2022 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jul 27, 2018 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters